GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

Formatech to Fill and Finish One Lot of KAI Pharmaceuticals’ SHPT Drug at No Charge

  • KAI Pharmaceuticals’ KAI-4169 will be the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.

    KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients. Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?